Institute of General Practice, Rostock University Medical Center, Doberaner Str. 142, 18057, Rostock, Germany.
Institute of Medical Biometry and Epidemiology, Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
BMC Fam Pract. 2019 Jun 25;20(1):87. doi: 10.1186/s12875-019-0977-9.
Does an intervention designed to foster patient-centered communication and shared decision making among GPs and their patients with poorly controlled type 2 diabetes mellitus reduce the level of HbA1c.
The DEBATE trial is a cluster-randomized controlled trial conducted in German primary care and including patients with type 2 diabetes mellitus having an HbA1c level of 8.0% (64 mmol/mol) or above at the time of recruitment. Data was measured before intervention (baseline, T0), 6-8 months (T1), 12-14 months (T2), 18-20 months (T3), and 24-26 months (T4) after baseline. Main outcome measure is the level of HbA1c.
In both, the intervention and the control group the decline of the HbA1c level from T0 to T4 was statistically significant (- 0.67% (95% CI: - 0.80,-0.54%; p < 0.0001) and - 0.64% (95% CI: - 0.78, - 0.51%; p < 0.0001), respectively). However, there was no statistically significant difference between both groups.
Although the DEBATE trial was not able to confirm effectiveness of the intervention tested compared to care as usual, the results suggest that patients with poorly controlled type 2 diabetes are able to improve their blood glucose levels. This finding may encourage physicians to stay on task to regularly approach this cohort of patients.
The trial was registered at ISRCTN registry under the reference ISRCTN70713571 .
一项旨在促进全科医生与控制不佳的 2 型糖尿病患者之间以患者为中心的沟通和共同决策的干预措施,是否能降低糖化血红蛋白(HbA1c)水平。
DEBATE 试验是一项在德国初级保健中进行的群组随机对照试验,纳入了招募时 HbA1c 水平为 8.0%(64mmol/mol)或以上的 2 型糖尿病患者。数据在干预前(基线,T0)、6-8 个月(T1)、12-14 个月(T2)、18-20 个月(T3)和 24-26 个月(T4)后进行测量。主要观察指标为 HbA1c 水平。
在干预组和对照组中,HbA1c 水平从 T0 到 T4 的下降均具有统计学意义(-0.67%(95%CI:-0.80,-0.54%;p<0.0001)和-0.64%(95%CI:-0.78,-0.51%;p<0.0001))。然而,两组之间没有统计学上的显著差异。
尽管 DEBATE 试验未能证实与常规护理相比,所测试的干预措施的有效性,但结果表明,控制不佳的 2 型糖尿病患者能够改善其血糖水平。这一发现可能鼓励医生继续定期关注这一患者群体。
该试验在 ISRCTN 注册处注册,注册号为 ISRCTN70713571。